ALK-Abello and Catalent to increase Grazax production
ALK-Abello will be funding a new DKK 300m (€40.3m) production line dedicated to its oral grass pollen allergy vaccine at Catalent Pharma Solutions' UK facility.
Archives for August 28, 2007
Amgen vs. Roche: patent trial to kick off
A US judge has backed Amgen's court motion, ruling that Roche's Mircera infringes one of its composition patents. Roche is standing firm against the allegations.
Novartis Hep C drug clears Phase II
A long-acting biologic being co-developed by Novartis to treat chronic hepatitis C virus (HCV) has triggered a $40m (€29.3m) milestone for its development partner after clearing Phase II trials in April.
Octreotide prolonged release form ticking all the boxes
Results from a Phase II study of a prolonged release formulation of octreotide look encouraging for the treatment of acromegaly, according to Ambrilia Biopharma.
Novartis expands on Rasilez news
24 hours after announcing EU approval of its hypertension drug Rasilez (aliskiren), Novartis has unveiled plans for a major expansion to production facilities in Switzerland.
GSK drug could prove unlikely saviour for Vioxx
Vioxx (rofecoxib) might have been offered a lifeline with the news that the drug could be used safely, so long as drugs such as GlaxoSmithKline's investigational dyslipidaemia compound are administered at the same time.
FDA considers combo allergy pill
A single tablet formulation combining two major allergy treatments has been accepted for review by the US Food and Drug Administration (FDA).